COLOGNE, GERMANY / ACCESSWIRE / June 28, 2018 / CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors today announced the ...

COLOGNE, GERMANY / ACCESSWIRE / July 27, 2021 / CEVEC Pharmaceuticals GmbH (CEVEC), the leading provider of high-performance cell technology for scalable manufacturing of advanced bio-therapeutics, ...

Cologne, Germany, December 21, 2010 / b3c newswire / - CEVEC Pharmaceuticals, the developer of the CAP® protein expression system derived from human amniocytes, today announced that Rainer Christine ...

Cytiva’s acquisition of CEVEC Pharmaceuticals strengthens the company’s cell line development and biomanufacturing capabilities. Cytiva has acquired CEVEC Pharmaceuticals, a Germany-based provider of ...

ELEVECTA(R) takes viral vector manufacturing to the next level to serve the rapidly growing market of gene therapy applications Growing serum-free in suspension, ELEVECTA(R) producer cell lines enable ...

Jed Seifert says his greatest moment of last year was the day he walked into Stakes Manufacturing in Eastlake to see an older couple he didn’t recognize. After introductions were made, Seifert learned ...

The new cell-line producing platform enables fully scalable production of high-performance adeno-associated virus vectors. On April 28, 2020, Cevec Pharmaceuticals announced the launch of the ELEVECTA ...

CEVEC Pharmaceuticals has announced its new management team: Wolfgang Kintzel remains Chief Executive Officer, Dr. Nicole Faust is appointed Chief Scientific Officer, Dr. Hartmut Tintrup is appointed ...

CAP-T system will be used to manufacture protein antigen being evaluated in preclinical studies. Swiss vaccines company Pevion Biotech negotiated an exclusive license option agreement with Cevec ...

The ELEVECTA(R) Technology produces Stable Producer Cell Lines designed to enable fully scalable, high-performance AAV vector production Under the agreement, CEVEC grants UCB rights and options to the ...